By Elias Schisgall

Galapagos' board of directors agreed to wind down the Belgian pharmaceutical company's cell therapies activities in a decision that will impact roughly 365 employees globally.

The move will also lead to the closure of sites in Leiden, the Netherlands; Basel, Switzerland; and Shanghai, and as well as two U.S.-based sites in Pittsburgh and Princeton, N.J.

The company said in October that it intended to wind down cell therapy activities, but that the decision was subject to consultations with works councils in Belgium and the Netherlands. Those consultations were completed, and the board decided to move ahead with the wind-down, the company said Monday.

Galapagos Chief Executive Officer Henry Gosebruch said the company would move forward with "transformational business development" following the wind-down. The company will continue managing its non-cell therapy activities.

The company said last month it was evaluating strategic alternatives after an autoimmune disease treatment failed to meet one of its trial goals.

Galapagos American Depository Receipts rose 6.1% to $34.74 in after-hours trading.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

January 05, 2026 16:18 ET (21:18 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.